What are the CDC recommendations for the use of varicella-zoster immune globulin (VariZIG) in the treatment of varicella-zoster virus (VZV) infection?

Updated: Feb 15, 2019
  • Author: Wayne E Anderson, DO, FAHS, FAAN; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD  more...
  • Print
Answer

In July 2013, the CDC issued updated recommendations for the use of varicella-zoster immune globulin (VariZIG) to reduce the severity of VZV infection, extending the window for postexposure prophylaxis for those at high risk for severe varicella. [7, 8] The FDA's original approval of VariZIG recommended use within 4 days, but subsequent studies have shown that the treatment is effective for up to 10 days after exposure.

Other recommendations include the use of VariZIG in the following patients:

  • Immunocompromised patients without evidence of immunity

  • Newborn infants whose mothers have varicella symptoms between 5 days before and 2 days after delivery

  • Hospitalized premature infants born at 28 weeks of gestation or later whose mothers do not have evidence of immunity to varicella

  • Hospitalized premature infants born at less than 28 weeks of gestation or who weigh less than 1000 g at birth, regardless of their mothers' evidence of immunity to varicella

  • Pregnant women without evidence of immunity


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!